Recipharm invests in Brexit preparations

‘Brexit taskforce’ will see Recipharm prioritise its preparations and invest in the necessary capabilities and equipment to ensure seamless operations post March 2019.
Recipharm has established a dedicated taskforce to manage the potential impact of Brexit on its organisation.
With less than a year until the UK exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations and customers.
The formation of the ‘Brexit taskforce’ will see Recipharm prioritise its preparations and invest in the necessary capabilities and equipment within its UK and European facilities to ensure seamless operations post March 2019.
Commenting on the announcement, Thomas Beck, Senior Vice President Quality Management at Recipharm, said: “While many stakeholders in the pharma industry are campaigning for a ‘soft’ exit from the EU, there is a risk that the complexity of the regulatory landscape will increase dramatically if a ‘hard’ Brexit takes place. Consequently, we are preparing for all eventualities.”
“Recipharm’s presence in both the UK and mainland Europe means we are well positioned to support our customers post-Brexit. We are also adept at streamlining processes across geographies and dealing with third party importations into Europe due to our global facilities.”
To strengthen its organisation ahead of Brexit, Recipharm has plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing and administration requirements that are expected.
Thomas continued: “Brexit has the potential to bring about additional resource demands. We are focused on ensuring our team is equipped to handle the potential challenges so that our customers continue to receive the same level of service. We also expect to see a greater demand for outsourced manufacturing services from UK-based marketing authorisation holders (MAHs) wishing to supply to Europe and are preparing our team to meet this demand.”
“We firmly believe that the challenge needs to be faced in a pragmatic way and have been liaising with both the EMA and relevant politicians to communicate that the finer details of Brexit and the implications on our industry need to be discussed as a matter of priority.”

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance